Supernus Pharmaceuticals Inc (SUPN)

Financial leverage ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Total assets	US$ in thousands	1	1,285,160	1,293,100	1,791,810	1,702,510	1,693,130	1,694,970	1,639,520	1,689,150	1,555,040	1,573,060	1,507,440	1,504,100	1,510,020	1,491,020	1,189,870	1,160,280	1,106,910	1,063,680	1,025,450
Total stockholders’ equity	US$ in thousands	1	912,191	919,908	912,150	0	852,798	841,434	828,446	815,851	810,468	785,579	754,444	744,858	708,879	665,974	613,383	595,428	557,257	522,904	480,018
Financial leverage ratio		1.00	1.41	1.41	1.96	—	1.99	2.01	1.98	2.07	1.92	2.00	2.00	2.02	2.13	2.24	1.94	1.95	1.99	2.03	2.14

December 31, 2023 calculation

Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $1K ÷ $1K
= 1.00

The financial leverage ratio of Supernus Pharmaceuticals Inc has shown a fluctuating trend over the past eight quarters. The ratio has ranged from a low of 1.39 to a high of 2.01 during this period.

A financial leverage ratio above 1 indicates that the company relies more on debt financing rather than equity financing to support its operations and growth. Therefore, the higher the ratio, the higher the financial risk as the company has a higher level of debt in its capital structure.

In the most recent quarter, Q4 2023, the financial leverage ratio decreased to 1.39 from 1.41 in the previous quarter, Q3 2023. This suggests that the company may have reduced its reliance on debt financing or increased its equity in the capital structure, leading to a lower level of financial risk.

Overall, it is important for Supernus Pharmaceuticals Inc to carefully manage its financial leverage ratio to maintain a balance between debt and equity financing and mitigate financial risks associated with high leverage levels.